683 Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

683 Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-335,880	Closed	-$1.73M	–	162
2020 Q2	$1.73M	Buy	+335,880	New	+$2.12M	0.14%	86
2019 Q4	–	Sell	-197,872	Closed	-$1.67M	–	193
2019 Q3	$1.67M	Buy	+197,872	New	+$1.47M	0.19%	69
2019 Q1	–	Sell	-187,500	Closed	-$3M	–	196
2018 Q4	$3M	Sell	187,500 -57,480	-23%	-$1.26M	0.18%	76
2018 Q3	$8.11M	Sell	244,980 -5,020	-2%	-$129K	0.53%	43
2018 Q2	$5.65M	Hold	250,000	–	–	0.38%	50
2018 Q1	$7.25M	Hold	250,000	–	–	0.64%	44
2017 Q4	$6.97M	Sell	250,000 -1,581	-0.6%	-$49.1K	0.59%	49
2017 Q3	$9.18M	Sell	251,581 -82,594	-25%	-$2.55M	0.97%	37
2017 Q2	$7.42M	Buy	334,175 +5,175	+2%	+$40.7K	1.09%	33
2017 Q1	$1.94M	Buy	329,000 +229,000	+229%	+$1.65M	0.3%	64
2016 Q4	$540K	Buy	+100,000	New	+$667K	0.04%	97

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

683 Capital Management's AVEO Position: Q3 2020 in Review

683 Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2020, closing a stake of 335,880 shares — an estimated $1.73M sold.

683 Capital Management first reported a position in AVEO in Q4 2016 and held it in 11 quarters. The position peaked at $9.18M in Q3 2017. 63 funds tracked by Wall St. Rank hold AVEO as of Q3 2020.

683 Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
683 Capital Management sold 335,880 AVEO Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.73M.
683 Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2016 and held it in 11 quarters.
683 Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $9.18M in Q3 2017.
63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2020.

Based on 683 Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.